Human IFNA8 Recombinant Protein (HEK293 Expression) — Tag Free
Price range: $250.00 through $6,600.00
HEK293 × Chaperone-Assisted Technology
Produced using our proprietary Z-Active® platform — HEK293 mammalian expression with chaperone-assisted folding for proper disulfide bonding, N-linked glycosylation, and 5–10× higher bioactivity vs Leading Suppliers.
Overview
Interferons (IFN) are a family of cytokines with potent antiviral, antiproliferative and immunomodulatory properties, classified based on their binding specificity to cell surface receptors (1). Human IFNA2 was originally cloned in the early ‘80s and now more than a dozen closely related IFN alpha subtypes have been identified in both the human and mouse genome, each sharing about 80% amino acid (aa) sequence homology (2-4). Structurally, type I IFNs belong to the class of five helical-bundle cytokines, with the IFNA subtypes containing 2 conserved disulfide bonds (5). The extracellular domain (ECD) of mature human IFNA8, also known as IFN‑alpha B2, shares 60% aa sequence identity with mouse homolog. The type I IFNs bind to the interferon alpha receptor (IFNAR), which consists of two subunits: IFNAR1 (alpha-subunit) and IFNAR2 (beta -subunit) (6, 7). Individual IFNA subtypes are known to display unique efficacies to viral protection, and IFNA8 is the most potent IFNA, judging by both antiviral and antiproliferative activities (8). The reason for this higher potency is unstructured tail region of IFNA8 that gains structure during complex formation and might explain the differences in activity between IFNAs (8). IFNA8 has been shown to exhibit antiproliferative and cytotoxic effects on renal cancer cell (RCC) lines and chronic myelogenous leukemia (CML)-derived cell lines (9, 10).
Specifications
- Species: human
- Expression System: HEK293
- Sequence: Cys24-Glu189
- Tag: Tag Free
- Molecular Weight: 19.5 Kda
- Purity: > 95% by Tris-Bis PAGE;> 95% by SEC-HPLC
- Endotoxin: < 1 EU/μg of the protein by LAL method.
- UniProt/Swiss-Prot: P32881
- Available Sizes: 10 µg, 50 µg, 1 mg
Bioactivity
Measured in anti-viral assays using HeLa human cervical epithelial carcinoma cells infected with encephalomyocarditis (EMC) virus. The EC50 for this effect is 1.20-12.0 pg/mL.
Formulation & Reconstitution
Formulation: 0.22 μm filtered solution of PBS, pH 7.4.
Reconstitution: 0.2 mg/mL in sterile PBS, pH7.4
Storage & Stability
Aliquot and store at -80°C. Avoid repeated freeze/thaw cycles.
Quality Assurance
Each lot is tested for purity (SDS-PAGE, SEC-HPLC), endotoxin levels (LAL method), and bioactivity. A Certificate of Analysis (COA) is provided with every order.
Safety Data Sheets & Documentation
Protocols & Support
Reconstitution Protocol
1. Briefly centrifuge the vial to collect lyophilized powder at the bottom.
2. Reconstitute in sterile deionized water or PBS to a concentration of 0.2–1.0 mg/mL.
3. Gently pipette up and down to dissolve. Do not vortex.
4. Aliquot and store at -20°C to -80°C. Avoid repeated freeze-thaw cycles.
Download Data Sheet
Complete product data sheet including batch-specific QC data, sequence information, and storage guidelines.
Download PDF Data Sheet
